Regulatory
Published · Updated · 2 min read
DEC: clotrimazole risk management plan summary describes routine safety measures
What it means for practice
The plan for clotrimazole vaginal suppositories provides for routine risk minimisation and ongoing pharmacovigilance. The absence of listed risks in the summary should not be interpreted as an absence of possible adverse reactions.
Summary
The DEC website hosts a risk management plan summary for Clofan, vaginal suppositories 500 mg, KUSUM LLC, Ukraine. According to the available abstract, the document concerns clotrimazole and describes the approach to safety monitoring and risk minimisation during use of this formulation.
What the plan provides for
The approach relies on routine risk minimisation measures, including packaging information and dispensing conditions. The abstract mentions prescription status among these measures but does not specify the product’s dispensing category. Ongoing pharmacovigilance is also planned to monitor adverse reactions.
According to the abstract, the plan currently lists no identified or potential risks. No additional post-authorisation studies are required. The safety information is aligned with data for the reference medicinal product.
Limits of interpretation
This information describes a risk management plan rather than clinical study results. The absence of listed risks in this summary is not a statement that adverse reactions do not occur. The available abstract provides no quantitative estimates of their frequency or description of new restrictions on use.
Source
-
Клофан, супозиторії вагінальні 500 мг, ТОВ “КУСУМ”, Україна.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
